Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash from Operations: 2016-2024

Historic Cash from Operations for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$32.8 million.

  • Mereo BioPharma Group's Cash from Operations rose 2.79% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 8.30%. This contributed to the annual value of -$32.8 million for FY2024, which is 55.38% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Cash from Operations stood at -$32.8 million for FY2024, which was down 55.38% from -$21.1 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Cash from Operations peaked at -$7.1 million during FY2021, and registered a low of -$48.8 million during FY2022.
  • Moreover, its 3-year median value for Cash from Operations was -$32.8 million (2024), whereas its average is -$34.3 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Cash from Operations soared by 80.60% in 2021 and then plummeted by 591.30% in 2022.
  • Mereo BioPharma Group's Cash from Operations (Yearly) stood at -$36.4 million in 2020, then skyrocketed by 80.60% to -$7.1 million in 2021, then plummeted by 591.30% to -$48.8 million in 2022, then surged by 56.72% to -$21.1 million in 2023, then crashed by 55.38% to -$32.8 million in 2024.